Licensing
Facilitating next-generation innovations to shape the future of medicine
The emergence of advanced, novel therapeutics has transformed the way pharmaceutical and biotech companies are approaching drug discovery and development. With the surge of cell, gene, and immunologic therapies, we are pleased to offer an extensive array of licensing opportunities designed to support you in developing your pipeline.
Proven expertise to multiply your impact:
- Scale your capacity to shorten setup periods and reduce development times
- Bolster your pharmaceutical projects with viral vector engineering and manufacturing and cell line engineering
- Expand your offerings by licensing IP like Pin-point (TM) Base Editing Platform, LentiBOOST® Viral vector-based gene editing, and more
For research use only. Not for use in diagnostic procedures.
Pin-point Base Editing Platform
Novel editing system for a more controlled approach to gene disruption and base correction with the potential for multiplex gene editing capabilities.
Gene Delivery Systems
LentiBOOST® lentivirus transduction enhancer is a highly effective, non-cytotoxic transduction enhancer of lentiviral vectors.
Gene Expression Systems
Streamlining biotherapeutic development with gene expression systems, providing speed, reliability, and adaptability at all stages of the process.
Virus Screening
Offering promising tools to accelerate high-throughput screening projects aiming to identify lead candidates.
